^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    22h
    PRIMAVERA: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. (clinicaltrials.gov)
    P1/2, N=161, Recruiting, AstraZeneca | N=110 --> 161 | Trial completion date: May 2026 --> Apr 2029 | Trial primary completion date: May 2026 --> Apr 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    1d
    Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis. (PubMed, Int J Cancer)
    The current findings suggest that obesity is associated with a lower incidence of BM involvement and mortality in patients with HL. The obesity together with HL mechanistically influences systemic and local BM cytokine production, thereby impacting HL fate.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
    1d
    Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    5d
    A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov)
    P1, N=9, Terminated, Aurigene Discovery Technologies Limited | N=42 --> 9 | Trial completion date: Jan 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Feb 2026; Patient recruitment problems
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AU7R-104 • XL114
    5d
    SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105 (clinicaltrials.gov)
    P1, N=17, Terminated, Aurigene Discovery Technologies Limited | N=40 --> 17 | Recruiting --> Terminated; Patient recruitment problems.
    Enrollment change • Trial termination • First-in-human
    7d
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    7d
    Adriamycin, Vinblastine and Dacarbazine With Immunotherapy Achieves Complete Metabolic Response in a Patient With Classical Hodgkin Lymphoma and Dyskeratosis Congenita. (PubMed, J Hematol)
    To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.
    Journal • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine
    8d
    A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Merck Sharp & Dohme LLC | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    8d
    The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    9d
    S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    11d
    SSTR2 expression in EBV-positive and EBV-negative lymphomas. (PubMed, J Hematop)
    Our study demonstrates that EBV infection is required, but not sufficient, to upregulate SSTR2 in classic Hodgkin lymphoma, but not in other EBV-associated lymphomas. We also provide data to suggest that SSTR2 is associated with "higher-grade" germinal center-derived B-cell lymphomas in EBV-negative non-Hodgkin lymphomas.
    Retrospective data • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)